KALA BIO, Inc. (KALA) Financials

KALA Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 12.3 million 1.6 million
Dec. 31, 2025 9.5 million 2.5 million
Sept. 30, 2025 25.0 million 33.7 million
June 30, 2025 36.1 million 39.3 million

KALA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -2.9 million -471000
Dec. 31, 2025 -4.6 million 401000
Sept. 30, 2025 -10.9 million 2.0 million
June 30, 2025 -7.7 million 2.2 million

KALA Net Income

No data available :(

KALA Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 8.8 million - -
Dec. 31, 2025 7.6 million - -
Sept. 30, 2025 21.1 million - 1.5 million
June 30, 2025 31.9 million 18.8 million 1.6 million

KALA Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 8.1 million
Dec. 31, 2025 556994
Sept. 30, 2025 7.0 million
June 30, 2025 6.5 million

KALA Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 16000 61000 1.7 million -
Dec. 31, 2025 16000 312000 9.9 million -
Sept. 30, 2025 16000 6.1 million 4.5 million -
June 30, 2025 16000 6.2 million 4.6 million -

KALA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - 54000
Dec. 31, 2025 - 54000
Sept. 30, 2025 - 128000
June 30, 2025 - 67000

KALA Revenue by Segment
Graph available only for paid members. Upgrade to see it.

KALA

Price: $0.90

52 week price:
0.59
1030.00

Earnings Per Share: -102.01 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 3.0 million

Ebitda: -9.9 million

Market Capitalization: 17.1 million

Links: